Vitamin D and iPTH Levels Vary by Season
In a large study of dialysis patients, serum 25-hydroxyvitamin D levels peaked in summer and declined in winter.
Secondary Hyperparathyroidism
Oral Evocalcet Appears Effective for SHPT
In 2 small trials of Japanese patients with SHPT on dialysis, evocalcet treatment reduced iPTH to target levels in a majority of patients within 30 to 32 weeks.
TPTx Plus Autotransplantation May Provide Better Long-Term PTH Control
At 6 months after surgery, just 6.7% TPTx + AT had parathyroid hormone levels exceeding 200 pg/mL, compared with 38.9% of SPTx patients
Vitamin K Antagonists, Liver Dysfunction Implicated in Calciphylaxis
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
Target Vitamin D Levels in CKD With SHPT May Need Updating
In an analysis of 2 randomized trials of patients with stage 3 to 4 chronic kidney disease, iPTH suppression did not occur until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL.
Post-Parathyroidectomy Hungry Bone Syndrome Less Problematic in PD
In a single center study, hungry bone syndrome developed in fewer patients on peritoneal dialysis than hemodialysis after parathyroidectomy.
Pretransplantation PTH May Influence the Risk for Tertiary HPT
In a study, patients with the highest preoperative levels of PTH tended to have higher postoperative levels than other transplant recipients.
SHPT Linked With Low Bone Density in CKD
In a study of patients with chronic kidney disease, secondary hyperparathyroidism was associated with high risk for reduced bone mineral density, particularly at the hip.
SGLT2 Inhibitor Increases Serum Phosphate, PTH, and FGF23
Study supports the hypothesis that altered tubular phosphate handling drives the increase in serum phosphate during SGLT2 inhibition.
Genetic Variant in FGF23 Tied With Cardiovascular Risks in HD
In a study, having the single nucleotide polymorphism rs11063112 in fibroblast growth factor 23 was associated with a 32% greater risk for cardiovascular mortality.
Next post in Secondary Hyperparathyroidism
